Late Onset Alzheimer's Disease Senile Dementia. Symmetric Enlargement Of Cerebral Sulci Suggests That Cortical Gray Matter Is Affected. Axial Cut Away View. (Photo By BSIP/UIG Via Getty Images)
FDA approves an Alzheimers drug
01:45 - Source: CNN
CNN  — 

Two House committees have launched an investigation into the approval and pricing of the Alzheimer’s disease drug aducanumab, made by the company Biogen and sold under the brand name Aduhelm.

The US Food and Drug Administration approved the drug earlier this month under its “accelerated approval” program, although an FDA advisory committee concluded last year that there was not enough evidence to support the effectiveness of the treatment.

Biogen announced in early June that the wholesale cost of treatment – which requires an infusion once every four weeks – is about $4,312 per infusion, making the annual cost about $56,000 for a high dose.

“We have serious concerns about the steep price of Biogen’s new Alzheimer’s drug Aduhelm and the process that led to its approval despite questions about the drug’s clinical benefit,” House Democrats Carolyn Maloney and Frank Pallone Jr. said in a statement issued Friday about the investigation by the Committee on Oversight and Reform and the Committee on Energy and Commerce.